Meeting
2021 ASCO Annual Meeting
Moderator
Presenter
Shirish M. Gadgeel, MD
Henry Ford Cancer Institute, Henry Ford Health System
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Case-Based Panel
Session Title
Making Heads or Tails Out of Checkpoint Inhibitor Combination Therapy for First-Line Advanced Non–Small Cell Lung Cancer
Track
Lung Cancer,Immunotherapy
Similar Videos & Slides
Videos & Slides
2021 ASCO Annual Meeting
Open label phase II trial of cabozantinib (cabo) in patients with metastatic castrate resistant prostate cancer (mCRPC) and known amplifications or activating mutations in gene targets who have received prior anti-androgen therapy.
Speaker: Jones T. Nauseef, MD, PhD
Videos & Slides
2021 Genitourinary Cancers Symposium
Network meta-analysis (NMA) comparing the efficacy of enzalutamide versus apalutamide, darolutamide, and bicalutamide for treatment of nonmetastatic (nm) castration-resistant prostate cancer (CRPC).
Speaker: Tomasz M. Beer, MD
Videos & Slides
2021 Genitourinary Cancers Symposium
PROSPER subgroup analysis by age and region: Overall survival and safety in men with nonmetastatic castration-resistant prostate cancer receiving androgen deprivation therapy plus enzalutamide.
Speaker: Ugo De Giorgi, MD, PhD
Videos & Slides
2012 ASCO Annual Meeting
TERRAIN: A randomized, double-blind, phase II study comparing MDV3100 with bicalutamide (Bic) in men with metastatic castrate-resistant prostate cancer (CRPC).
Speaker: Edwina S. Baskin-Bey, MD